News
News

The latest updates from AFAR.

Grantee in the News: Reisa Sperling to lead two new Alzheimer’s trials, Yahoo Finance reports

May 15
2019

Grantee in the News: Reisa Sperling to lead two new Alzheimer’s trials, Yahoo Finance reports View MoreBACK

On May 13, 2019, Yahoo Finance featured AFAR expert Reisa Sperling, MD in an article announcing that Dr. Sperling will lead a two new Alzheimer’s clinical trials.

Dr. Sperling is a 2003 Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76) scholar.

The investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat and the investigational anti-amyloid beta (Ab) protofibril antibody BAN2401, which are currently being evaluated as potential treatments for early Alzheimer's disease (AD), have been selected by the Alzheimer’s Clinical Trial Consortium (ACTC) as potential treatments to be evaluated in upcoming clinical studies targeting primary prevention (A3 Study) and secondary prevention (A45 Study) of AD.

The ACTC, funded by the National Institute on Aging at the National Institutes of Health, provides the infrastructure for academic clinical trials in Alzheimer's Disease and related dementias.

These studies will be conducted with funding from various sources including the United States National Institute on Aging (NIA), part of the National Institutes of Health, and Eisai.

Read more here.

 





View MoreBACK TO TOP